Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Peroxiredoxins as potential therapeutic targets in glioblastoma.

2017/25/B/NZ7/00388

Keywords:

glioblastoma peroxiredoxins therapeutic targets

Descriptors:

  • NZ7_14: Pharmacy, pharmacotherapy, pharmacology

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

woj. mazowieckie

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr hab. Monika Szeliga 

Number of co-investigators in the project: 3

Call: OPUS 13 - announced on 2017-03-15

Amount awarded: 602 700 PLN

Project start date (Y-m-d): 2018-01-19

Project end date (Y-m-d): 2023-01-18

Project duration:: 60 months (the same as in the proposal)

Project status: Project settled

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Equipment purchased [PL]

  1. Inkubator CO2 (45 000 PLN)

Information in the final report

  • Publication in academic press/journals (3)
  1. Menadione potentiates auranofin-induced glioblastoma cell death.
    Authors:
    Szeliga M., Rola R.
    Academic press:
    Int J Mol Sci. (rok: 2022, tom: 23, strony: 15712), Wydawca: mdpi
    Status:
    Published
    DOI:
    10.3390/ijms232415712. - link to the publication
  2. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.
    Authors:
    Szeliga M.
    Academic press:
    Neurochemistry International (rok: 2022, tom: 153, strony: 105256), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.neuint.2021.105256 - link to the publication
  3. Conoidin A, a covalent inhibitor of peroxiredoxin 2, reduces growth of glioblastoma cells by triggering ROS production.
    Authors:
    Szeliga M., Rola R.
    Academic press:
    Cells (rok: 2023, tom: 12, strony: 1934), Wydawca: mdpi
    Status:
    Published
    DOI:
    10.3390/cells12151934. - link to the publication

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy